SBIR Phase I: Preparation and Characterization of Polymer based Biodegradable Nanoparticles of Novel Inhibitors of Cell Proliferation

这个小企业创新研究（SBIR）第一阶段项目将研究基于聚合物的新型细胞增殖抑制剂的可生物降解纳米颗粒的制备和表征。 基于聚合物的生物可降解纳米颗粒的开发是由通过增加药物对疾病部位的生物利用度、包含递送到癌组织、增加药物溶解度和最小化全身副作用来改善总体存活率和生活质量的期望引导的。我们最近发现了具有特定和独特性质的新型抗细胞增殖化合物，使其成为实体瘤的理想治疗方法。本研究的主要目的是制备和表征我们的化合物的纳米颗粒制剂。本项目所研究的化合物在临床开发中有很高的成功机会，因为药物是局部给药的，产生毒性的变化很小，而且化合物的分子靶点被证明是安全的治疗靶点。这种新型制剂的开发将允许在肿瘤部位持续递送新型细胞增殖抑制剂。 该项目更广泛的影响/商业潜力：对于几种类型的人类恶性肿瘤，迫切需要开发可局部递送至肿瘤部位的新型治疗药物。本项目中化合物研究的纳米颗粒制剂的成功开发，如果成功，将通过降低癌症治疗的成本和改善癌症化疗患者的生存和生活质量来降低医疗成本。在拟议的研究中开发的纳米颗粒制剂可以取代几种联合化疗方案，这些方案除了非常昂贵外还具有许多副作用。

This Small Business Innovation Research (SBIR) Phase I project will study the preparation and characterization of polymer based biodegradable nanoparticles of novel inhibitors of cell proliferation. The development of polymer-based biodegradable nanoparticles is guided by the desire to improve overall survival and quality of life by increasing the bioavailability of drug to the site of disease, containing delivery to the cancerous tissues, increasing drug solubility, and minimizing systemic side effects. We have recently discovered novel anti-cell proliferative compounds with specific and unique properties that make them an ideal treatment for solid tumors. The main aim of this study is preparation and characterization of nanoparticle formulations of our compounds. The compounds studied in this project have a high chance of success during clinical development because of the drugs are administered locally, which has very little change of producing toxicity, but also the molecular targets of the compound are proven to be safe therapeutic targets. Development of such novel formulations will allow sustained delivery of novel inhibitors of cell proliferation in the tumor site. The broader impact/commercial potential of this project: Development of novel therapeutics that could be delivered locally into tumor site is critically needed for several types of human malignancies. Successful development of nanoparticle formulations of the compounds studies in this project will, if successful, reduce healthcare costs by reducing the cost of cancer therapy and by improving the survival and quality of life for many patients under cancer chemotherapy. The nanoparticle formulations developed under the proposed studies could replace several combination chemotherapy regimens that have numerous side effects in addition to being very expensive.